FindTrial
Sign In

A study to assess the effect of vitamin D deficiency correction on platelet counts in immune thrombocytopenia patients.

Impact of treatment of vitamin D deficiency on platelet response in immune thrombocytopenia patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/06/008751
Enrollment
154
Registered
2017-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D693- Immune thrombocytopenic purpura

Interventions

Intervention1: Vitamin D: Among immune thrombocytopenia patients those who are tested and found to have vitamin D deficiency will be given the standard replacement dose of vitamin D (as recommended) a

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Group A Newly diagnosed patients (age more than or equal to 13years) of ITP (diagnosed within 1 month of enrolment for present study) Group B Patients (age more than or equal to 13 years) already diagnosed to be having ITP (diagnosed for >1 month before enrollment to present study) and with platelet count between 20000-50000/µl on stable/decreasing dose of steroids/immunosuppressants/immunomodulators.

Exclusion criteria

Exclusion criteria: Group A and Group B (i) Cases of Evanâ??s syndrome (ii) Cases of SLE, HCV infection (secondary ITP cases) (iii) Those patients who have already received replacement doses of vitamin D before enrolment into the study (iv) Patients who are having already diagnosed malabsorption syndrome, chronic kidney disease. (v) Patients who are on antiepileptics before enrolling into the study. In addition to these those patients having mucosal bleeds and severe cutaneous bleeds(Extensive ecchymoses) will be excluded in group B

Design outcomes

Primary

MeasureTime frame
Response : For patients with platelet count 20,000/µl, response will be platelet count more than or equal to 20,000/µl or a greater than 2-times the baseline platelet count, whichever is higher and with absence of spontaneous bleeding episodes. For patients with platelet count 20,000 to 50,000/µl response will be platelet count more than or equal to 50,000/µl or a greater than 2- times the baseline platelet count, whichever is higher and with absence of spontaneous bleeding episodesTimepoint: 5 weeks—

Secondary

MeasureTime frame
To assess the prevalence of vitamin D deficiency in newly diagnosed immune thrombocytopenia patients (In group A) Timepoint: During enrollment into the study (Using group A)—

Countries

India

Contacts

Public ContactVijesh V S

JIPMER

drkvv@rediffmail.com9442604554

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026